Press release
Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Xuanzhu Biopharmaceutical,
Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non–Small Cell Lung Cancer Pipeline
DelveInsight reports that over three key companies are actively working on developing more than three therapies for the treatment of Anaplastic Lymphoma Kinase (ALK) positive, advanced non-small cell lung cancer.
Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Overview:
Lung cancer continues to be the leading cause of cancer-related deaths worldwide. The introduction of tyrosine kinase inhibitors (TKIs) has markedly improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) harboring targetable mutations. In 3-7% of NSCLC cases, rearrangements in the anaplastic lymphoma kinase (ALK) gene result in persistent activation of pathways that drive tumor growth and survival.
Advancements in diagnostic tools, such as reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS), have enhanced the accuracy of detecting ALK rearrangements, enabling more tailored treatment strategies. Crizotinib, the first FDA-approved ALK TKI, achieved response rates of 57-74%, but most patients develop resistance within about a year. Resistance arises from both ALK-dependent mutations and ALK-independent mechanisms, including activation of alternative signaling pathways.
Second- and third-generation ALK TKIs have shown high efficacy in both systemic disease and central nervous system (CNS) metastases, though the optimal treatment sequence is still under investigation. The expanding range of available ALK inhibitors offers new hope for prolonging progression-free and overall survival in ALK-positive NSCLC patients.
Request for a detailed insights report on Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer pipeline insights [https://www.delveinsight.com/report-store/anaplastic-lymphoma-kinase-alk-positive-advanced-nonsmall-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Therapeutics Market.
Key Takeaways from the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Pipeline Report
*
DelveInsight's report on the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer pipeline highlights a strong development landscape, with over three active companies working on more than three therapies for this indication.
*
Key players include Xuanzhu Biopharmaceutical, Fochon Pharmaceuticals Ltd, Shenzhen TargetRx, Inc., and others, all focused on advancing novel treatments to enhance the therapeutic landscape.
*
Notable candidates in development include XZP-3621, SAF-189, and additional promising therapies at various stages of the pipeline.
*
On December 18, 2024, the FDA approved ensartinib for adult patients with ALK-positive locally advanced or metastatic NSCLC who had not previously been treated with an ALK inhibitor. Approval was supported by results from the eXALT3 trial, which reported a median progression-free survival (PFS) of 25.8 months with ensartinib versus 12.7 months with crizotinib.
*
Earlier, on April 18, 2024, the FDA approved alectinib as an adjuvant therapy for patients with ALK-positive NSCLC following tumor resection. Findings from the ALINA trial demonstrated that alectinib provided a significant improvement in disease-free survival compared to platinum-based chemotherapy.
Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer market.
Download our free sample page report on Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer pipeline insights [https://www.delveinsight.com/sample-request/anaplastic-lymphoma-kinase-alk-positive-advanced-nonsmall-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Emerging Drugs
*
XZP-3621: Xuanzhu Biopharmaceutical
*
SAF-189: Reata Pharmaceuticals
Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Companies
Multiple leading companies are actively working on therapies for Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer, with Xuanzhu Biopharmaceutical having a drug candidate currently in the advanced Phase III clinical trial stage.
DelveInsight's report covers around 3+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Therapies and Key Companies: Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Clinical Trials and advancements [https://www.delveinsight.com/report-store/anaplastic-lymphoma-kinase-alk-positive-advanced-nonsmall-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment
- Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Assessment by Product Type
- Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer By Stage
- Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Assessment by Route of Administration
- Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Assessment by Molecule Type
Download Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Sample report to know in detail about the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer treatment market @ Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Therapeutic Assessment [https://www.delveinsight.com/sample-request/anaplastic-lymphoma-kinase-alk-positive-advanced-nonsmall-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Current Treatment Patterns
4. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Late-Stage Products (Phase-III)
7. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Discontinued Products
13. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Product Profiles
14. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Key Companies
15. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Key Products
16. Dormant and Discontinued Products
17. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Unmet Needs
18. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Future Perspectives
19. Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Pipeline Reports Offerings [https://www.delveinsight.com/report-store/anaplastic-lymphoma-kinase-alk-positive-advanced-nonsmall-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=anaplastic-lymphoma-kinase-alk-positive-advanced-nonsmall-cell-lung-cancer-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-xuanzhu-biopharmaceutical]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Xuanzhu Biopharmaceutical, here
News-ID: 4142783 • Views: …
More Releases from ABNewswire
Falkin Pest Control Ensures Peace of Mind for Stoneham, CO Communities with Resi …
Residents and businesses in Stoneham, CO, rely on Falkin Pest Control's expert services to keep properties pest-free, secure, and protected year-round.
Stoneham, CO - Falkin Pest Control is dedicated to offering reliable pest management solutions for both residential and commercial properties in the Stoneham area. Providing effective and environmentally responsible pest control services, the company ensures that residents and business owners can enjoy a pest-free environment.
Whether it's tackling common pests like…
Facility Pest Control Educates Simi Valley, CA on the Hidden Signs of Pest Activ …
In Simi Valley, Facility Pest Control is raising awareness about overlooked indicators of pest problems, teaching homeowners how to detect issues before they spread.
Simi Valley, CA - Facility Pest Control, a family-owned and locally operated pest management company, is providing valuable education to homeowners and businesses in Simi Valley, CA, about the often-overlooked signs of pest activity. Many infestations begin quietly, with pests hiding in walls, attics, or outdoor spaces,…
How Facility Pest Control Ensures Safe Pest Treatments for Families and Pets Acr …
In Brentwood, CA, Facility Pest Control prioritizes family and pet safety by using eco-conscious treatments that eliminate pests while keeping homes secure.
Brentwood, CA - Facility Pest Control, a family-owned and locally operated business, is committed to providing safe, effective, and eco-friendly pest control Brentwood [https://facilitypestcontrol.com/pest-control-brentwood-ca/] services for families and pets throughout Brentwood, CA. With a focus on using natural, organic products, the company ensures that pest treatments are not only…
Real Estate Agents in Cape Coral, FL, Achieve Top Ranking with 95% Quality Score …
Cape Coral, FL - Re/Max Realty Team: Bob Ashworth PA & Jenn Spears Real Estate Agents in Cape Coral FL has been recognized with the prestigious Quality Business Award for 2025, achieving an exceptional quality score of 95%. This honor places the team among less than 1% of registered businesses in America that have earned this distinguished recognition for outstanding customer service and business excellence.
The award evaluation process utilized advanced…
More Releases for ALK
ALK ELISA Kits Market Outlook and Future Projections for 2030
The alk elisa kits market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
ALK-1 Antibody Market Outlook and Future Projections for 2030
The alk-1 antibody market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the current…
ALK-positive Non-Small Cell Lung Cancer Pipeline: Companies Advancing Targeted T …
The therapeutic landscape for ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC), a genetically defined subset of lung cancer driven by ALK gene rearrangements, is undergoing a significant transformation. Biopharmaceutical companies are shifting focus from traditional chemotherapy to precision medicine approaches that directly inhibit ALK-driven oncogenic signaling. With multiple generations of ALK inhibitors now available and resistance mechanisms emerging, the spotlight is on next-generation inhibitors, combination regimens, and CNS-penetrant therapies designed…
Allergy Shots Market | ALK Abello, Aimmune Therapeutics, Allergy Therapeutics, A …
The global allergy shots market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the allergy shots market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth of the…
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Analysis By Major Manufa …
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market: Driven factors and Restrictions factors
The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the future. The information presented is based on historical milestones…
ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market 2023: Analysis By Regional Outl …
Los Angeles, United State:  The latest report published by QY Research presents a thorough analysis of the global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market. The research report evaluates the ever-changing market dynamics that are expected to impact the trajectory of the overall market. Analysts studied the historical achievements of the market and compared it to the current market trends, to chart the trajectory. For a detailed discussion about the global ALK Tyrosine…
